Universitätsklinikum Leipzig

Medizin ist unsere Berufung.

UCL UNIVERSITÄRES KREBSZENTRUM

ÜBERSICHT ZU ONKOLOGISCHEN STUDIEN AM UNIVERSITÄTSKLINIKUM LEIPZIG

Stand: Juni 2021

LIEBE KOLLEGINNEN UND KOLLEGEN,

der Studienflyer gibt Ihnen Übersicht über die aktiven onkologischen Therapiestudien am Universitätsklinikum Leipzig, in denen wir Patienten die bestmögliche Versorgung nach aktuellem Stand der klinischen Forschung anbieten können.
Sie finden die Studien nach Indikationen sortiert. Aus Gründen der Übersichtlichkeit sind nur interventionelle Studien aufgelistet. Bitte nehmen Sie mit der Studienassistenz Kontakt auf, wenn Sie weitere Informationen zu einer Studie erhalten wollen. Sie dürfen sich auch immer an das Studienteam des Universitären Krebszentrums wenden. Wir helfen Ihnen gerne weiter.
Wir freuen uns auf eine ausgezeichnete klinisch-wissenschaftliche Kooperation mit Ihnen und hoffen im Sinne der Patienten, dass unser Leipziger Studienportfolio weiterhin intensiv genutzt wird.

Mit kollegialen Grüßen

Prof. Dr. Florian Lordick
Direktor des UCCL

Dr. Ivonne Haffner
Leitung
klinische Forschung

Dr. Gertraud Stocker
ärztliche Leitung
Studienteam

ADENOKARZINOM MAGEN UND GEJ

Primärtherapie, neoadjuvant/perioperativ/ postoperativ

VESTIGE	Sophia Schmidt	0341 9712596

Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (N+ and/or R1): an open label randomized controlled phase-2-study (VESTIGE)

EORTC Innovation	Sophia Schmidt	0341 9712596

Integration of Trastuzumab, with or without Pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer: the INNOVATION-TRIAL

RACE	Sophia Schmidt	0341 9712596

Neoadjuvant Radiochemotherapy versus Chemotherapy for Patients with Locally Advanced, Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ)

CARDIA-Trial	Nicole Kreuser	0341 9712590

Surgery for adenocarcinoma of the gastroesophageal junction (GEJ) type II: Transthoracic esophagectomy vs. transhiatal extended gastrectomy

ProPec	Nicole Kreuser	0341 9712590

Phase II Pilotstudie zur Verminderung der Peritonealkarzinose-Inzidenz nach kurativer Gastrektomie eines Magenkarzinoms oder Adenokarzinoms des gastroösophagealen Übergangs durch hypertherme intraperitoneale Chemoperfusion

PREVENT	Nicole Kreuser	0341 9712590

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction Type II/III adenocarcinoma

1. Linie palliativ lokal fortgeschritten oder metastasiert

Spotlight	Sophia Schmidt	0341 9712596

A phase 3, global, multi-center, double-blind, randomized, efficacy study of Zolbetuximab (IMAB362) plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with Claudin (CLDN)18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Destiny 03	Sophia Schmidt	0341 9712596

Phase 1/2b multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of Trastuzumab Deruxtecan (DS-8201a) monotherapy and combinations in adult subjects with HER2 overexpressing gastric cancer

Mahogany	Sophia Schmidt	0341 9712596

Phase 2/3 multicenter, international study in patients with metastatic or locally advanced, treatment-naïve, HER2-positive gastric or gastroesophageal junction cancer

2. Linie palliativ, lokal fortgeschritten/metastasiert

CA018-003 FRACTION	Sophia Schmidt	0341 9712596

A Phase 2, fast real-time assessment of combination therapies in immuno-oncology study in participants with advanced gastric cancer (FRACTION-gastric cancer)

Ramiris	Sophia Schmidt	0341 9712596

Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with adavanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy

20180290-AMG199	Sophia Schmidt	0341 9712596

A global phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the half-life extended bispecific T-cell engager AMG 199 in subjects with MUC17-positive gastric and gastroesophageal junction cancer

20180292-AMG910	Sophia Schmidt	0341 9712596

A global phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of the half-life extended bispecific T-cell engager AMG 910 in subjects with Claudin 18.2-positive gastric and gastroesophageal junction adenocarcinoma

PLATTENEPHITELKARZINOM ÖSOPHAGUS

Primärtherapie

Scyscraper	Sophia Schmidt	0341 9712596

A phase III, randomized, double-blind, placebo-controlled study of Atezolizumab with or without Tiragolumab (anti-TIGIT antibody), in patients with unresectable locally advanced esophageal squamous cell carcinoma

HEPATOZELLULÄRES KARZINOM (HCC)

Primärtherapie

IRITACE	Carolin Straube	0341 9712328

Transarterielle Chemoembolization (TACE) mit Irinotecan und Mitomycin C im Vergleich zur TACE mit Doxorubicin bei Patienten mit nicht kurativ behandelbarem hepatozellulärem Karzinom - IRITACE - eine randomisierte multicenter Phase 2 Studie. Eine Studie der „German Alliance for Liver Cancer" (GALC)

1. Linie palliativ, lokal fortgeschritten/metastasiert

CA209-9DW	Madlen Steger	0341 9712474

A randomized, multi-center, Phase 3 study of Nivolumab in combination with Ipilimumab compared to Sorafenib or Lenvatinib as first-line treatment in participants with advanced hepatocellular Carcinoma

2. Linie palliativ, lokal fortgeschritten/metastasiert

I4T-MC-JVDE (REACH 2)	Katja Hirschmann	0341 9712474

Randomized, double-blind, placebo-controlled, phase 3 study of Ramucirumab and Best Supportive Care (BSC) versus placebo and BSC as second-line treatment in patients with hepatocellular carcinoma and elevated baseline Alpha-Fetoprotein (AFP) following first-line therapy without first Sorafenib

CaboRISE	Carolin Straube	0341 9712474

A phase II study evaluating reduced starting dose and dose escalation of Cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis

KOLOREKTALES KARZINOM

Primärtherapie

Radianc	Sandra Schuster	0341 9716681

Radiochemotherapy +/- Durvalumab for locally-advanced anal carcinoma. A multicenter, randomized, phase II trial of the German Anal Cancer Study Group

ACO/ARO/ AIO-18.1	Sandra Schuster	0341 9716681

Preoperative oxaliplatin-based chemoradiotherapy and consolidation chemotherapy versus fluorouracil-based chemoradiotherapy for MRI-defined intermediate and high-risk rectal cancer patients. A randomized phase III trial of the German Rectal Cancer Study Group

ACO/ARO/ AIO-18.2	Sophia Schmidt	0341 9712596

Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group

CIRCULATE	Nicole Kreuser	0341 9712590

Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung

Primärtherapie Lebermetastasen

PARLIM	Yvonne Kurth	0341 9712226

Panitumumab after resection of liver metastases from colorectal cancer in RAS wild-type patients

1. Linie palliativ, lokal fortgeschritten/metastasiert

FIRE-4	Sophia Schmidt	0341 9712596

Randomised study of the efficacy of Cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus Cetuximab

MoLiMor	Sophia Schmidt	0341 9712596

Modulation of the FOLFIRI-based standard 1st-line therapy with cetuximab, controlled by monitoring the RAS mutation load by liquid biopsy in RAS-mutated mCRC patients

2. Linie palliativ, lokal fortgeschritten/metastasiert

RAMTAS	Yvonne Kurth	0341 9712226

A Phase IIb study with run in safety phase of Ramucirumab in combination with TAS102 vs. TAS102 monotherapy refractory metastatic colorectal cancer patients

3. Linie palliativ, lokal fortgeschritten/metastasiert

FIRE-4	Sophia Schmidt	0341 9712596

Randomised study of the efficacy of Cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus Cetuximab

CHOLANGIOKARZINOM

1. Linie palliativ, lokal fortgeschritten/metastasiert

FIGHT II	Yvonne Kurth	0341 9712226

A Phase 3, open-Label, randomized, active-controlled, multicenter study to evaluate the efficacy and safety of Pemigatinib versus Gemcitabine plus Cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement (FIGHT-302)

PCIA203/18	Yvonne Kurth	0341 9712226

A multi-centre, randomised, open-label, phase 2 study to assess the safety, tolerability and efficacy of Fimaporfin-induced photochemical internalisation of Gemcitabine complemented by Gemcitabine/Cisplatin chemotherapy versus Gemcitabine/Cisplatin alone in patients with inoperable cholangiocarcinoma

LUNGENKARZINOM

Supportivtherapie

ANAM-17-21	Patricia Berger	0341 9712674

A phase III randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of ANAMORELIN HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC

1. Linie palliativ, lokal fortgeschritten/metastasiert

MK-3475-671-06	Patricia Berger	0341 9712674

A Phase III, randomized, double-blind trial of Platinum doublet Chemotherapy +/- Pembrolizumab as neoadjuvant/adjuvant therapy for participants with resectable stage II, IIIa, and resecetable IIIb NSCLC (Keynote-671)

ABP	Patricia Berger	0341 9712674

APB – Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+NSCLC) patients by deep phenotyping

PROSTATAKARZINOM

Primärtherapie

LAP-01	Dr. Holze	0341 9717629

Prospektive Studie zum Vergleich der Roboter-assistierten und der konventionellen laparoskopischen/endoskopischen radikalen Prostatektomie

ProLy	Dr. Holze	0341 9717629

Prospektive Erfassung der Lymphozelenhäufigkeit bei robotisch–assistierten-minimal-invasiven radikalen Prostatektomien unter Bildung eines peritonealen Schwenk-lappens: eine randomisierte kontrollierte verblindete klinische Multicenter-Studie

ZERVIXKARZINOM

Primärtherapie

	Juliane Gehrt	0341 9711379

Neue Tumoroperationen auf der Grundlage der ontogenetischen Anatomie für die Behandlung des Zervix- und Vaginalkarzinoms: TMMR, KMMR, EMMR, LEER und tLNE

VULVAKARZINOM

Primärtherapie

	Juliane Gehrt	0341 9711379

Vulvafeldresektion und anatomische Rekonstruktion: Neues operatives Konzept für die Lokalbehandlung des Vulvakarzinoms

OVARIALKARZINOM

Primärtherapie

AGO23/ DUO-O	Juliane Gehrt	0341 9711379

A phase III randomised, double-blind, placebo-controlled, multicentre study of Durvalumab in combination with chemotherapy and Bevacizumab, followed by maintenance Durvalumab, Bevacizumab and Olaparib in newly diagnosed advanced ovarian cancer patients

2. Linie palliativ, lokal fortgeschritten/metastasiert

COMPASS	Juliane Gehrt	0341 9711379

Comparison of quality of life between Trabectedin/PLD and standard Platinum-based therapy in patients with Platinum sensitive recurrent ovarian, fallopian tube and peritoneal cancer

ENDOMETRIUMKARZINOM

Primärtherapie

	Juliane Gehrt	0341 9711379

Prospektive monozentrische Beobachtungsstudie: Peritoneale mesometriale Resektion (PMMR), totale mesometriale Resektion (TMMR+) und therapeutische Lymphonodektomie (tLNE) – neue Tumoroperation auf der Grundlage der ontogenetischen Anatomie zur Behandlung des frühen Endometriumkarzinoms (FIGO-Stadium I und II)

1+2. Linie palliativ, lokal fortgeschritten/metastasiert

SIENDO/KCP-330-024	Juliane Gehrt	0341 9711379

A randomized, double-blind, phase 3 trial of maintenance with Selinexor / Placebo after combination chemotherapy for patients with advanced or recurrent endometrial cancer

MAMMAKARZINOM

Primärtherapie

ADAPTcycle	Juliane Gehrt	0341 9711379

Adjuvante, auf dynamische Marker adjustierte, personalisierte Therapie zum Vergleich einer endokrinen Behandlung plus Ribociclib mit Chemotherapie bei Hormonrezeptor-positivem, HER2-Rezeptor negative, mittleres Risiko aufweisendem frühen Brustkrebs

CHECKMATE 7FL	Juliane Gehrt	0341 9711379

Randomisierte, multizentrische, doppelblinde, Placebo-kontrollierte Phase 3-Studie zu Nivolumab vs. Placebo in Kombination mit neoadjuvanter Chemotherapie und adjuvanter endokriner Therapie bei Patienten mit primärem Estrogenrezeptor-positivem, humaner-epidermaler-Wachstumsfaktor-Rezeptor-2-negativem Hochrisiko-Brustkrebs (ER+/HER2-)

1. Linie palliativ, lokal fortgeschritten/metastasiert

EPIKB3-CBYL719H12301	Sophia Schmidt	0341 9712596

A phase III, multicenter, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation

CONTESSA TRIO	Juliane Gehrt	0341 9711379

Eine multizentrische Studie der Phase II zu Tesetaxel plus drei verschiedenen PD-(L)1-Inhibitoren bei Patienten mit dreifach negativem, lokal fortgeschrittenem oder metastasierendem Brustkrebs und einer Monotherapie mit Tesetaxel bei älteren Patienten mit HER2-negativem, lokal fortgeschrittenem oder metastasierendem Brustkrebs

ZNS-TUMORE

Primärtherapie

EORTC-1709-BTG	Nadja Talhi	0341 9718210

A phase III trial of Marizomib in combination with standard Temozolomide-based radiochemotherapy versus standard Temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma

DOSIS	Nadja Talhi	0341 9718210

Dose-intensified image-guided fractionated stereotactic body radiation therapy for painful spinal metastases (DOSIS) versus conventional radiation therapy: a phase II randomised controlled trial

SNOXA	Nadja Talhi	0341 9718210

Single-arm, Dose-Escalation, Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination with Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients with Unmethylated MGMT Promoter

EORTC IADL	Nadja Talhi	0341 9718210

Development of a questionnaire to measure instrumental activities of daily living (I-ADL) in patients with primary brain tumors and brain metastases: Phase IV international field testing

2. Linie palliativ, lokal fortgeschritten/metastasiert

RAGNAR (Solide high grade ZNS-Tumors)	Sandra Schuster	0341 9720546

A Phase 2 Study of Erdafitinib in subjects with advanced solid tumors and FGFR gene alteration

KOPF-HALS-KARZINOM

Primärtherapie

EORTC 1420	Nadja Talhi	0341 9718210

Phase III study assessing the "best of" radiotherapy compared to the "best of" surgery (trans-oral surgery (TOS)) in patients with T1-T2, N0-N1 oropharyngeal, supraglottic carcinoma and with T1, N0 hypopharyngeal carcinoma

ADRISK	Kathrin Vogel	0341 9725052

Postoperative adjuvant radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk

NadiHN	Kathrin Vogel	0341 9725052

An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating efficacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over 12 months in patients with advanced resectable HNSCC after surgery

1. Linie palliativ, lokal fortgeschritten/metastasiert

EORTC 1206	Kathrin Vogel	0341 9725052

Eine randomisierte Phase II Studie zur Untersuchung der Wirksamkeit und Sicherheit einer Chemotherapie gegenüber einer Androgendeprivationstherapie bei Patienten mit einem Wiederauftreten und/oder Metastasen eines Speicheldrüsenkrebses, welcher Androgen-Rezeptoren aufweist

KO-TIP-007	Kathrin Vogel	0341 9725052

A pivotal study of Tipifarnib in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS mutations who have failed at least one prior line of therapy

ISA101b	Kathrin Vogel	0341 9725052

Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zu Cemiplimab im Vergleich zur Kombination aus Cemiplimab und ISA101b bei der Behandlung von Patienten mit HPV16-positivem Oropharynxkarzinom (OPK)

2. Linie palliativ, lokal fortgeschritten/metastasiert

ISA101b	Kathrin Vogel	0341 9725052

Eine randomisierte, doppelblinde, placebokontrollierte Phase-2-Studie zu Cemiplimab im Vergleich zur Kombination aus Cemiplimab und ISA101b bei der Behandlung von Patienten mit HPV16-positivem Oropharynxkarzinom (OPK)

AbbVie M19-894	Kathrin Vogel	0341 9725052

A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 plus Tilsotolimod and Other Therapy Combinations in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

INTERLINK-1	Kathrin Vogel	0341 9725052

Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor

MELANOM

neoadjuvante Therapie

Pivotal PH-19IL2TNF-02/15	Silke Weidauer-Zuniga/ Anja Zeuner	0341 9718750/ 0341 9720015

A phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients

adjuvante Therapie

NIVO MELA	Mandy Dathe/ Silke Weidauer-Zuniga	0341 9718380/ 0341 9718750

A phase III randomized, controlled trial with adjuvant nivolumab treatment and biomarker-based risk stratification in in stage II high risk melanoma

lokal fortgeschritten oder metastasiert

MK-7902-003	Mandy Dathe/ Silke Weidauer-Zuniga	0341 9718380/ 0341 9718750

A phase 3 randomized, placebo-controlled trial to evaluate the safety and efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) versus Pembrolizumab alone as first-line intervention in participants with advanced melanoma

CA045-001	Silke Weidauer-Zuniga/ Anja Zeuner	0341 9718750/ 0341 9720015

A phase 3, randomized, open-label study of NKTR-214 combined with Nivolumab versus Nivolumab as first-line intervention in participants with advanced melanoma

V937-011	Mandy Dathe/ Silke Weidauer-Zuniga	0341 9718380/ 0341 9718750

A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma

MERKELZELL-KARZINOM

lokal fortgeschritten oder metastasiert

Merklin2	Anja Zeuner/ Silke Weidauer-Zuniga	0341 9720015/ 0341 9718750

A phase II, open label study to investigate the efficacy and safety of Domatinostat in combination with Avelumab in patients with advanced unresectable/metastatic merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy

PLATTENEPITHELZELLKARZINOM DER HAUT

lokal fortgeschritten oder metastasiert

AliCe	Silke Weidauer-Zuniga/ Mandy Dathe	0341 9718750/ 0341 9718380

Einarmige, offene, multizentrische Phase II Studie zur Untersuchung der klinischen Aktivität und Sicherheit von Avelumab in Kombination mit Cetuximab bei Studienteilnehmern mit nicht reserzierbarem Stadium III oder IV Plattenepithelkarzinom der Haut

Cerpass	Anja Zeuner/ Silke Weidauer-Zuniga	0341 9720015/ 0341 9718750

A randomized, controlled, open-label, phase 2 study of Cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma

SARKOM

rEECur	Sophia Schmidt	0341 9712596

International randomised controlled trial for the treatment of recurrent and primary refractory ewing sarcoma

SOLIDE TUMORE

ab 1. Linie palliativ, lokal fortgeschritten/metastasiert

RAGNAR	Nadja Talhi/ Sophia Schmidt	0341 9718210/ 03419712596

A phase 2 study of Erdafitinib in subjects with advanced solid tumors and FGFR gene alterations

MYELOISCHE ERKRANKUNGEN AML

Primärtherapie

AG-120 / CC-90012 / AGILE	Sascha Grabow	0341 9712621

Phase 3a Studie mit AG 120 bei Patienten mit akuter myeloischer Leukämie (AML) mit einer IDH1 Mutation

PALOMA	Sascha Grabow	0341 9712621

Primary comparison of liposomal Anthracycline based treatment versus conventional care strategies before allogenic stem cell transplantation in patients with higher risk MDS and oligoblastic AML – the PALOMA study

ASTX727-02	Nicole Thorn	0341 9712658

A phase 3, randomized, open-label, crossover study of ASTX727 (Cedazuridine and Decitabine fixed-dose combination) versus IV Decitabine in subjects with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML)

DaunoDouble	Sascha Grabow	0341 9712621

Randomized comparison between two dose levels of Daunorubicin and between one versus two cycles of induction therapy for adult patients with acute myeloid leukemia ≤ 65 years

Primärtherapie – Early Clinical Trials Unit Leipzig

74494550 AML1003 ELEVATE	Karolin Hubert	0341 9720363

An open-label, multicenter, phase 1b study of JNJ-74494550 (Cusatuzumab; Anti-CD70 monoclonal antibody) in combination with background therapy for the treatment of subjects with acute myeloid leukemia

IMGN632-0802	Karolin Hubert	0341 9720363

Phase 1b/2 study of IMGN632 monotherapy and in combination with Venetoclax and/or Azacytidine in CD123-Positive AML patients (relapsed and front-line)

Sekundärtherapie

M19-708	Sascha Grabow	0341 9712621

Randomized, open-label, phase III study of Venetoclax and Azacitidine versus standard of care as maintenance therapy for patients with acute myeloid leukemia in first remission after conventional chemotherapy

Rezidiv, refraktär

AML003 / ARMADA 2000	Nicole Thorn	0341 9712658

Phase III multicenter open-label randomized trial to evaluate efficacy and safety of CPI-613 in combination with high dose Cytarabine and Mitoxantrone (CHAM) compared to high dose Cytarabine and Mitoxantrone (HAM) in older patients (≥60 years) with relapsed/refractory acute myeloid leukemia (AML)

Mautitius	Nicole Thorn	0341 9712658

Midostaurin in MRD positive acute myeloid leukemia after allogeneic stem cell transplantation

Q-HAM	Nicole Thorn	0341 9712658

Quizartinib and high-dose Ara-C plus Mitoxantrone in relapsed/refractory AML with FLT3-ITD

SHAPE	Sascha Grabow	0341 9712621

Treatment of MDS/AML patients with an impending hematological relapse with Azacitidine alone or in combination with Pevonedistat - a randomized phase 2 trial

TUD-PEMAZA-068	Sascha Grabow	0341 9712621

MRD-guided treatment with Pembrolizumab and Azacitidine in NPM1mut AML patients with an imminent hematological relapse

ETAL3-ASAP	Katrin Stolle	0341 9713134

Evaluation of the impact of remission induction chemotherapy prior to allogeneic stem cell transplantation in relapsed and poor-response patients with AML

Rezidiv, refraktär – Early Clinical Trials Unit Leipzig

CA-4948-102	Karolin Hubert	0341 9720363

A phase 1, open label dose escalation trial evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered CA-4948 in patients with acute myelogenous leukemia or myelodysplastic syndrome

67571244 AML1001	Karolin Hubert	0341 9720363

A phase 1, first-in-human, dose escalation study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in subjects with relapsed or refractory AML or MDS

CD-TCR-001	Karolin Hubert	0341 9720363

A phase I/II, open-label, non-randomized, multicentre, dose-escalation clinical trial with control group to evaluate the safety, feasibility and preliminary efficacy of PRAME TCR modified T cells, MDG1011, in subjects with high risk myeloid and lymphoid neoplasms

DART - Studie	Karolin Hubert	0341 9720363

A phase 1/2, first-in-human, dose escalation study of MGD006, a CD123 x CD3 dual affinity re-targeting (DART) bi-specific antibody-based molecule, in patients with relapsed or refractory acute myeloid leukemia or intermediate-2/high risk myelodysplastic syndrome

ADVANCE II DCOne-002	Karolin Hubert	0341 9720363

An international, multicenter, open-label study to evaluate the efficacy and safety of two different vaccination regiments of immunotherapy with allogenic dendritic cells, DCP-001, in patients with acute myeloid leukaemia that are in remission with persistent MRD

IMGN632-0802	Karolin Hubert	0341 9720363

Phase 1b/2 study of IMGN632 monotherapy and in combination with Venetoclax and/or Azacytidine in CD123-positive AML patients (relapsed and front-line)

APL

Primärtherapie

APOLLO	Dr. rer. nat. Andrea Bendig	0341 9713061

Eine randomisierte Phase-III-Studie zum Vergleich von Arsentrioxid (ATO) in Verbindung mit ATRA und Idarubicin versus ATRA in Kombination mit einer Anthracyclin-basierten Chemotherapie (AIDA) bei Patienten mit neu diagnostizierter, akuter Promyelozytenleukämie mit Hochrisikomerkmalen

MDS

Primärtherapie

FGCL-4592-082	Karolin Hubert	0341 9720363

A phase 3 randomized double-blind placebo-controlled study investigating the efficacy and safety of Roxadustat (FG-4592) for treatment of anemia in patients with lower risk myelodysplastic syndrome (MDS) with low red blood cell (RBC) transfusion burden (LTB)

COMMANDS	Karolin Hubert	0341 9720363

A phase 3, open-label, randomized study to compare the efficacy and safety of Luspatercept (ace-536) versus Epoetin alfa for the treatment of anemia due to ipss-r very low, low or intermediate risk myelodysplastic syndromes (MDS) in ESA naïve subjects who require red blood cell transfusions

ACE-536-LTFU-001	Katja Hammann	0341 9713131

A phase 3B, open-label, single-arm, rollover study to evaluate long-term safety in subjects who are participated in other Luspatercept (ACE-536) clinical trails

M15-954 VERONA	Sascha Grabow	0341 9712621

A randomized, double-blind, phase 3 study evaluating the safety and efficacy of Venetoclax in combination with Azacitidine in patients newly diagnosed with higher-risk myelodysplastic syndrome (higher-risk MDS)

Primärtherapie – Early Clinical Trials Unit Leipzig

SLN124-002	Karolin Hubert	0341 9720363

A randomised, single-blind, placebo-controlled, phase 1, single-ascending and multiple-dose study in adult subjects with alpha/beta-thalassaemia and very low- and low-risk myelodysplastic syndrome to investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic response of SLN124

Rezidiv, refraktär

IDEAL	Sascha Grabow	0341 9712621

A single-arm phase II multicenter study of IDH2 (AG 221) inhibitor in patients with IDH2 mutated myelodysplastic syndrome – IDEAL

63935937 MDS3001	Katja Hammann	0341 9713131

A study to evaluate Imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA) treatment

IDH2 Post Allo	Katrin Stolle	0341 9713134

Prospective, open-label, non-randomized with 2 single noncomparative arms, multicenter phase-II trial– Enasidenib as consolidation or salvage therapy for patients with IDH2 Mutation with Relapse of AML, MDS, and CMML after allogeneic SCT

SHAPE	Sascha Grabow	0341 9712621

Treatment of MDS/AML patients with an impending Hematological relapse with Azacitidine alone or in combination with Pevonedistat - a randomized phase 2 trial

PALOMA	Sascha Grabow	0341 9712621

Primary comparison of liposomal Anthracycline based treatment versus conventional care strategies before allogenic stem cell transplantation in patients with higher risk MDS and oligoblastic AML – the PALOMA study

BoHemE	Sascha Grabow	0341 9712621

A prospective longitudinal cohort study to investigate the interactions of bone and hematopoiesis in the elderly

Rezidiv, refraktär – Early Clinical Trials Unit Leipzig

CA-4948-102	Karolin Hubert	0341 9720363

A phase 1, open label dose escalation trial evaluating the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered CA-4948 in patients with acute myelogenous leukemia or myelodysplastic syndrome

DART - Studie	Karolin Hubert	0341 9720363

A phase 1/2, first-in-human, dose escalation study of MGD006, a CD123 x CD3 dual affinity re-targeting (DART) bi-specific antibody-based molecule, in patients with relapsed or refractory acute myeloid leukemia or intermediate-2/high risk myelodysplastic syndrome

67571244 AML1001	Karolin Hubert	0341 9720363

A phase 1, first-in-human, dose escalation study of JNJ-67571244 (bispecific antibody targeting CD33 and CD3) in subjects with relapsed or refractory AML or MDS

64619178 EDI1001	Karolin Hubert	0341 9720363

A phase 1, first-in-human, open-label study of the safety, pharmacokinetics, and pharmacodynamics of JNJ-64619178, an inhibitor of protein arginine methyltransferase 5 (PRMT5) in subjects with advanced cancers

CD-TCR-001	Karolin Hubert	0341 9720363

A phase I/II, open-label, non-randomized, multicentre, dose-escalation clinical trial with control group to evaluate the safety, feasibility and preliminary efficacy of PRAME TCR modified T cells, MDG1011, in subjects with high risk myeloid and lymphoid neoplasms

SLN124-002	Karolin Hubert	0341 9720363

A randomised, single-blind, placebo-controlled, phase 1, single-ascending and multiple-dose study in adult subjects with alpha/beta-thalassaemia and very low- and low-risk myelodysplastic syndrome to investigate the safety, tolerability, pharmacokinetic, and pharmacodynamic response of SLN124

MPN

Sekundärtherapie

SRA-MMB-301	Dr. rer. nat. Andrea Bendig	0341 9713061

A randomized, open-label, phase 3 study to evaluate the activity of Momelotinib (MMB) or Best Available Therapy (BAT) in transfusion dependent subjects with primary myelofibrosis (PMF), post-polycythemia vera (PV) myelofibrosis, or post-essential thrombocythemia (ET) myelofibrosis who were previously treated wth JAK inhibitor therapy

Sekundärtherapie – Early Clinical Trials Unit Leipzig

MANIFEST	Karolin Hubert	0341 9720363

A phase 1/2 study of CPI-0610, a small molecule inhibitor of BET Proteins: phase 1 (dose escalation of CPI-0610 in patients with hematological malignancies) and phase 2 (dose expansion of CPI0610 with and without Ruxolitinib in patients with myelofibrosis)

CML

Primärtherapie

FASCINATION	Dr. rer. nat. Andrea Bendig	0341 9713061

Frontline Asciminib combination in chronic phase CML

Rezidiv, refraktär

ENDURE / CML-IX	Dr. rer. nat. Andrea Bendig	0341 9713061

Efficacy and safety of pegylated proline Interferon alpha 2b (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitor therapy - a randomized phase II, multicenter trial with post-study follow-up

DasaHIT trial	Dr. rer. nat. Andrea Bendig	0341 9713061

DasaHIT trial, (Dasatinib Holiday for Improved Tolerability) Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naive disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line)

PONDEROSA	Dr. rer. nat. Andrea Bendig	0341 9713061

Observational study on CML patients in any phase treated with Ponatinib (IclusigR) at any dose

MULTIPLES MYELOM

Primärtherapie

AGMT_MM-2	Jenny Dietrich	0341 9720364

A randomized Phase II, 2-armed study in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) comparing Carfilzomib + Thalidomide + dexamethasone (KTd) versus Carfilzomib + Lenalidomide + dexamethasone (KRd) induction therapy with respect to response rates and investigating a Carfilzomib (K) monotherapy maintenance strategy

AGMT_MM-3 DEFENCE	Jenny Dietrich	0341 9720364

A randomized Phase II, 2-armed study in transplant ineligible (TI) patients with newly diagnosed multiple myeloma (NDMM) comparing Carfilzomib + Thalidomide + dexamethasone (KTd) versus Carfilzomib + Lenalidomide + dexamethasone (KRd) induction therapy with respect to response rates and investigating a Carfilzomib (K) monotherapy maintenance strategy

DSMM_XVII	Jenny Dietrich	0341 9720364

Elotuzumab (E) in combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following autologous stem cell transplant in newly diagnosed multiple myeloma and subsequent maintenance with Elotuzumab and Lenalidomide versus single-agent Lenalidomide

Rezidiv, refraktär

68284528 MMY3002 Cartitude4	Jenny Dietrich	0341 9720364

A phase 3 randomized study comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) therapy directed against BCMA vs Carfilzomib and Dexamethasone (Kd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with relapsed and Lenalidomide-refractory multiple myeloma

DREAMM 8	Jenny Dietrich	0341 9720364

A phase III, multicenter, open-Label, randomized study to evaluate the efficacy and safety of Belantamab Mafodotin in combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in participants with relapsed/refractory multiple myelom

Rezidiv, refraktär – Early Clinical Trials Unit Leipzig

R5458-ONC-1826	Karolin Hubert	0341 9720363

A phase I/II study that will evaluate the safety and efficacy of an exciting new BiTE compound REGN5458 (anti-BCMA x anti-CD3) as treatment in adult patients with relapsed or refractory multiple myeloma

64007957 MMY1001	Karolin Hubert	0341 9720363

A phase 1/2, first-in-human, open-label, dose escalation study of Teclistamab, a humanized BCMA x CD3 bispecific antibody, in subjects with relapsed or refractory multiple myeloma

LYMPHATISCHE ERKRANKUNGEN

Primärtherapie

COPA-R-CHOP, UKM18_0021	Kitty Leuschel	0341 9713133

A prospective multicenter phase 2 study of the combination of the phosphatidylinositol-3-kinase inhibitor copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL)

Rezidiv, refraktär

MOR208C204 - B-MIND	Kitty Leuschel	0341 9713133

A phase II/III, randomized, multicentre study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in patients with relapsed or refractory diffuse large b-cell lymphoma (R-R DLBCL) who are not eligible for high-dose chemotherapy (HDC) and autologous stem-cell transplantation (ASCT) - B-MIND

AFM13-202, REDIRECT 107652	Kitty Leuschel	0341 9713133

A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive Peripheral T-Cell Lymphoma or transformed mycosis fungoides (REDIRECT)

R1979-ONC-1625	Katja Hammann	0341 9713131

An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory B-cell non-hodgkin lymphoma

Rezidiv, refraktär – Early Clinical Trials Unit Leipzig

MK4280-003	Karolin Hubert	0341 9720363

A phase 1b clinical study to evaluate safety and efficacy of a combination of MK-4280 an Prembrolizumab (MK-3475) in participants with hematologic malignancies

CC-220-NHL-001	Karolin Hubert	0341 9720363

A phase 1, multicenter, open-label study to assess safety, pharmacokinetics, and preliminary efficacy of Iberdomide (CC-220), alone and in combination with anti-CD20 in subjects with relapsed or refractory lymphomas

ALL

Primärtherapie

GMALL 08/2013	Kitty Leuschel	0341 9713133

Multizentrische randomisierte Studie zur Risiko- und subgruppenadaptierten Therapieoptimierung bei Erwachsenen mit ALL oder lymphoblastischen Lymphomen (Phase IV-Studie mit einem Phase III-Teil zur Evaluation der Sicherheit und Wirksamkeit von Nelarabin bei T-ALL)

EWALL-BOLD	Kitty Leuschel	0341 9713133

Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Blinatumomab

Rezidiv, refraktär

GMALL-MOLACT1-BLINA	Kitty Leuschel	0341 9713133

A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody Blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (Blast Successor Trial), phase II

Rezidiv, refraktär – Early Clinical Trials Unit Leipzig

20180257	Karolin Hubert	0341 9720363

A phase 1b open-label study to investigate the safety and pharmacokinetics of administration of subcutaneous Blinatumomab for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (R/R B-ALL)

HODGKIN LYMPHOM

Primärtherapie

HD21	Katja Hammann	0341 9713131

HD21- Therapieoptimierungsstudie für Patienten mit Erstdiagnose eines fortgeschrittenen klassischen Hodgkin Lymphoms: eine randomisierte Phase 3 Studie

Rezidiv

ADCT-301-201	Katja Hammann	0341 9713131

A phase 2, open-label, single-arm study to evaluate the efficacy and safety of Camidanlumab Tesirine (ADCT-301) in patients with relapsed or refractory hodgkin lymphoma

Rezidiv – Early Clinical Trials Unit Leipzig

MK4280-003	Karolin Hubert	0341 9720363

A phase 1b clinical study to evaluate safety and efficacy of a combination of MK-4280 an Prembrolizumab (MK-3475) in participants with hematologic malignancies

STAMMZELLTRANSPLANTATION

MOZOBL08363/ OPTIMOB	Katja Hammann	0341 9713131

Eine deutschlandweite systematische Untersuchung der Mobilisierung und Sammlung von hämatopoetischen Stammzellen bei schlecht mobilisierbaren Patienten vor autologer Stammzelltransplantation

JZP-381 15-007 (VOD)	Kitty Leuschel	0341 9713133

A phase 3, randomized, adaptive study comparing the efficacy and safety of Defibrotide vs. best supportive care in the prevention of hepatic veno-occlusive disease in adult and pediatric patients undergoing hematopoietic stem cell transplant

Graft versus Host Disease

INCB 39110-309 / GRAVITAS	Katrin Stolle	0341 9713134

A phase 3 study of Itacitinibor placebo in combination with corticosteroids as initial treatment for chronic graft versus host disease (GRAVITAS 309)

MC-MSC.1 IDUNN	Katrin Stolle	0341 9713134

A randomised, open-label, multicentre, phase 3 trial of first-line treatment with mesenchymal stromal cells MC0518 versus best available therapy in adult and adolescent subjects with steroid-refractory acute graft-versus host disease after allogeneic haematopoietic stem cell transplantation / IDUNN

CMV

SHP620-302 AURORA	Kitty Leuschel	0341 9713133

A phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of Maribavir compared to Valganciclovir for the treatment of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients

MCL

TRIANGLE	Katrin Stolle	0341 9713134

Autologous transplantation after a Rituximab/Ibrutinib/Ara-C containing induction in generalized mantle-cell lymphoma - a randomized European MCL Network Trial

ZELLTHERAPIE

Lymphom

M-2016-312, CART20.1	Kitty Leuschel	0341 9713133

A phase I/II safety, dose finding and feasibility trial of MB-CART20.1 in MB patients with relapsed or resistant CD20 positive B-NHL

Multiples Myelom

64007957 MMY1001	Karolin Hubert	0341 9720363

A phase 1/2, first-in-human, open-label, dose escalation study of Teclistamab, a humanized BCMA x CD3 bispecific antibody, in subjects with relapsed or refractory multiple myeloma

68284528 MMY3002 Cartitude4	Jenny Dietrich	0341 9720364

A phase 3 randomized study comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) therapy directed against BCMA vs Carfilzomib and Dexamethasone (Kd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with relapsed and Lenalidomide-refractory multiple myeloma

Early Clinical Trials Unit Leipzig

UC02-123-01	Karolin Hubert	0341 9720363

Multizentrische, offene Phase I Studie mit Dosissteigerungen für die Behandlung von Patienten mit CD123 positiven hämatologischen und lymphatischen Malignomen mittels gentechnisch veränderten T-Zellen, die universelle chimäre Antigen-Rezeptoren (UniCAR02-T) auf der Oberfläche tragen, und in Kombination mit einem CD123-spezifischen Zielmodul (TM123) verabreicht werden

PSYCHOONKOLOGISCHE VERSORGUNG

SALUT	Dr. Peter Esser	0341 9718800

Trauma- und belastungsbezogene Störungen bei hämatologischen Krebspatienten: Eine Interview-basierte Studie anhand aktualisierter diagnostischer Kriterien

Peer2Me	Dr. Diana Richter/ Dr. Kristina Geue	0341 9715426/ 0341 9715438

Peer2Me 2.0 – Evaluation eines Peer-MentoringProgramms zur Unterstützung junger Erwachsener mit Krebs

LUPE	Prof. Dr. phil. Anja Mehnert-Theuerkauf	0341 9718800

Längsschnittanalyse des psychoonkologischen Unterstützungsbedarfs bei Patienten und deren Angehörigen stratifiziert nach biopsychosozialen Einflussfaktoren

OptiScreen	Prof. Dr. phil. Anja Mehnert-Theuerkauf	0341 9718800

Optimierte psychoonkologische Versorgung durch einen interdisziplinären Versorgungsalgorhytmus – vom Screening zur Intervention

AYA-LE Längsschnitt 2	Dr. Kristina Geue	0341 9715438

Peer2Me 2.0 – Evaluation eines Peer-Mentoringprogramms zur Unterstützung junger Erwachsener mit Krebs

AOK	Prof. Dr. phil. Anja Mehnert-Theuerkauf	0341 9718800

Entwicklung eines Online-Coaches für Angehörige von an Krebs erkrankten Menschen

OnkoDigitrial	Prof. Dr. phil. Anja Mehnert-Theuerkauf	0341 9718800

OnkoDigitrial – digitale Begleitung von Patient:innen mit Krebserkrankung für eine nachhaltige Verbesserung der Lebensqualität

QualityOfLife	Prof. Dr. Andreas Hinz	0341 9718820

Gesundheitsbezogene Lebensqualität in der Onkologie und Palliativmedizin: Die Beziehung zwischen Wichtigkeits- und Zufriedenheitsurteilen

ONKO-STEP	Dr. Kristina Geue/ Prof. Dr. phil. Anja Mehnert-Theuerkauf	0341 9715438/ 0341 9718800

Wirksamkeit der kognitiv-behavioralen Online-Schreibtherapie Onko-STEP für Krebspatienten im jungen Erwachsenenalter – eine randomisierte kontrollierte Studie

ALL PÄDIATRIE

Primärtherapie

AIEOP-BFM ALL 2017	Kerstin Faulhaber	0341 9726173

Internationales kooperatives Behandlungsprotokoll Kinder und Jugendliche mit Akuter lymphatischer Leukämie

EsPhALL2017/ COGAALL1631	Kerstin Faulhaber	0341 9726173

Internationale Therapiestudie zur Behandlung von Kindern und Jugendlichen mit Philadelphia-positiver Akuter Lymphoblastischer Leukämie

Rezidiv

IntReALL HR 2010	Kerstin Faulhaber	0341 9726173

International study for treatment of high risk childhood relapsed ALL 2010

ALL-REZ BFM Register	Kerstin Faulhaber	0341 9726173

Beobachtungsstudie und Biobank für Rezidive einer akuten lymphatischen Leukämie im Kindes-und Jugendalter

AML PÄDIATRIE

Register

AML-BFM 2017	Kerstin Faulhaber	0341 9726173

Register zur Erfassung der myeloischen Leukämien bei Kindern und Jugendlichen

CML PÄDIATRIE

Primärtherapie

CML-paed-II-Register	Kerstin Faulhaber	0341 9726173

Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with philadelphia chromosome-positive chronic myeloid leukemia (CML)

MDS PÄDIATRIE

Primärtherapie

EWOG-MDS-2006	Kerstin Faulhaber	0341 9726173

Prospective non randomized multicenter study for epidemiology and characterization of myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) in childhood

LYMPHOM PÄDIATRIE

Primärtherapie

B-NHL 2013	Kerstin Faulhaber	0341 9726173

Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents

LBL 2018	Kerstin Faulhaber	0341 9726173

International cooperative treatment protocoll for children and adolescents with lymphoblastic lymphoma

NEUROBLASTOME PÄDIATRIE

Primärtherapie

Neuroblastom-Register	Kerstin Faulhaber	0341 9726173

Erfassung von Säuglingen, Kindern und Jugendlichen und jungen Erwachsenen mit neu diagnostizierten und/oder Rückfall eines neuroblastischen Tumors

Rezidiv

Metro-NB 2012	Kerstin Faulhaber	0341 9726173

Metronomische Behandlung von Kindern und Jugendlichen mit rezidiviertem oder progredientem Neuroblastom

NEPHROBLASTOME PÄDIATRIE

Primärtherapie

SIOP 2001/ GPOH	Kerstin Faulhaber	0341 9726173

Chemotherapy before and after surgery in treating children with Wilm's Tumor

HEPATOBLASTOME PÄDIATRIE

PHITT Studie	Kerstin Faulhaber	0341 9726173

Paediatric hepatic international tumor trial

HIRNTUMORE PÄDIATRIE

Primärtherapie

CPT-SIOP-2009	Kerstin Faulhaber	0341 9726173

Intercontinental multidisciplinary registry and treatment optimization study for patients with choroid plexus tumors

Kraniopharyn-geom Register 2019	Kerstin Faulhaber	0341 9726173

Multicenter registry for patients with childhood-onset craniopharyngioma, xanthogranuloma, cysts of Rathke's pouch, meningioma, pituitary adenoma, arachnoid cysts

SIOP Ependymoma II	Kerstin Faulhaber	0341 9726173

An international clinical program for the diagnosis and treatment of children, adolescents and young adults with ependymoma

I-HIT-Med	Kerstin Faulhaber	0341 9726173

For children, adolescents, and adults with medulloblastoma, ependymoma, pineoblastoma, CNS-primitive neuroectodermal tumours

EU-RHAB	Kerstin Faulhaber	0341 9726173

A multinational registry for rhabdoid tumors of any anatomical site

SIOP PNET 5 MB-LR und -SR	Kerstin Faulhaber	0341 9726173

Internationale, prospektive, randomisierte (SR) Phase II/III-Studie für Kinder älter als 3-5 Jahren und jünger als 16.0 Jahre (LR) bzw. geringer als 22.0 Jahre (SR) mit einem klinischen Standardrisiko-Medulloblastom und niedrigem (LR) bzw. durchschnittlichem (SR) biologischen Risikoprofil

HIT-HGG-2013	Kerstin Faulhaber	0341 9726173

International cooperative phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years

HIT-LOGGIC Register	Kerstin Faulhaber	0341 9726173

Prospektives multizentrisches Register für Kinder- und Jugendliche mit einem niedrig-gradigen Gliom

Rezidiv

HIT-REZ Register	Kerstin Faulhaber	0341 9726173

Multinationales multizentrisches Register für Kinder, Jugendliche und junge Erwachsene mit therapierefraktären oder rezidivierten Medulloblastomen, Pineoblastomen, primitiv neuroektodermalen Tumoren des ZNS (ZNS-PNET´s) und Ependymomen

SARKOME PÄDIATRIE

Primärtherapie

CWS 2007-HR	Kerstin Faulhaber	0341 9726173

Trial for localised high-risk rhabdomyosarcoma and rhabdomyosarcoma-like soft tissue sarcoma

rEECur	Kerstin Faulhaber	0341 9726173

International randomised controlled trial for the treatment of recurrent and primary refractory ewing sarcoma

CWS-Register SoTiSaR	Kerstin Faulhaber	0341 9726173

A registry for soft tissue sarcoma and other soft tissue tumours in children, adolescents, and young adults

COSS-Register	Kerstin Faulhaber	0341 9726173

Register der Cooperativen Osteosarkomstudiengruppe COSS

KEIMZELLTUMORE

Makei V	Kerstin Faulhaber	0341 9726173

Multizentrische prospektive Studie zu einem randomisierten Vergleich von Carboplatin mit Cisplatin bei extrakraniellen malignen Keimzelltumoren

SELTENE TUMORE PÄDIATRIE

GPOH-MET	Kerstin Faulhaber	0341 9726173

Register zur Erfassung maligner endokriner Tumoren im Kindes- und Jugendalter

STEP	Kerstin Faulhaber	0341 9726173

Seltene Tumoren, die nicht in prospektive Behandlungsstudien oder Register der GPOH eingeschlossen werden

INFORM	Kerstin Faulhaber	0341 9726173

Individualized therapy for relapsed malignancies in childhood

Lebertumor-register	Kerstin Faulhaber	0341 9726173

Register für Lebertumoren bei Kindern und Jugendlichen

NPC-2016	Kerstin Faulhaber	0341 9726173

A multicenter registry of nasopharyngeal cancer in children, adolescents and young adults

Retinoblastom-register	Kerstin Faulhaber	0341 9726173

Register für die Retinoblastomerkrankung in Deutschland und Österreich

NOTIZEN

ANSPRECHPARTNER/KONTAKT

Dr. Ivonne Haffner
Universitätsklinikum Leipzig
Leitung klinische Forschung
Liebigstraße 22, Haus 7; 04103 Leipzig
Tel.: 0341 9712570
E-Mail: studienzentrale.uccl@medizin.uni-leipzig.de

STUDIEN DURCHFÜHRENDE EINHEITEN AM UNIVERSITÄTSKLINIKUM LEIPZIG

Universitäres Krebszentrum Leipzig (UCCL)
Direktor Prof. Dr. Florian Lordick

Klinik und Poliklinik für Strahlentherapie
Direktor Prof. Dr. Rolf-Dieter Kortmann

Klinik und Poliklinik für Neurochirurgie
Direktor Prof. Dr. Jürgen Meixensberger

Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
Direktor Prof. Dr. Jan C. Simon

Medizinische Klinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie
komm. Direktor Prof. Dr. Thomas Berg

Klinik und Poliklinik für Urologie
Direktor Prof. Dr. Jens-Uwe Stolzenburg

Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde
Direktor Prof. Dr. Andreas Dietz

Klinik und Poliklinik für Frauenheilkunde
Direktorin Prof. Dr. Bahriye Aktas

Klinik und Poliklinik für Viszeral-, Transplantations-, Thorax- und Gefäßchirurgie
Direktoren Prof. Dr. Ines Gockel (Viszeralchirurgie) und Prof. Dr. Daniel Seehofer (Hepatobiliäre Chirurgie)

Medizinische Klinik und Poliklinik für Hämatologie, Zelltherapie und Hämostaseologie
Direktoren Prof. Dr. Uwe Platzbecker und Prof. Dr. Florian Lordick

Abteilung für Pneumologie
Leiter Prof. Hubert Wirtz

Abteilung Medizinische Psychologie und Medizinische Soziologie
Leiterin Prof. Dr. Anja Mehnert-Theuerkauf

Abteilung für Pädiatrische Onkologie, Hämatologie und Hämostaseologie
Leiter Prof. Dr. Holger Christiansen